Other ways to search: Events Calendar | UTHSC

GTx Provides First Quarter 2015 Financial Results


“I am pleased that we have been able to add to our platform of agents targeting hormonal receptors by successfully licensing the exclusive rights to the University of Tennessee Research Foundation’s SARD technology. We now have the opportunity to develop a potentially novel therapy to treat men with castration-resistant prostate cancer who do not respond or become resistant to currently approved therapies,” said Marc S. Hanover, CEO of GTx.

Top Publishers